Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high initial complete remission (CR) rates in B-cell acute lymphoblastic leukemia (B-ALL) patients, including those who relapsed after transplant. However, the duration of remission requires improvements. Whether bridging to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xing-yu, Zhang, Jian-ping, Zhao, Yan-li, Xiong, Min, Zhou, Jia-rui, Lu, Yue, Sun, Rui-juan, Wei, Zhi-jie, Liu, De-yan, Zhang, Xian, Yang, Jun-fang, Lu, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352576/
https://www.ncbi.nlm.nih.gov/pubmed/37469510
http://dx.doi.org/10.3389/fimmu.2023.1191382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352576/
https://www.ncbi.nlm.nih.gov/pubmed/37469510
http://dx.doi.org/10.3389/fimmu.2023.1191382

Ejemplares similares